translation agency

NLM AIDSLINE
New drug pricing consensus letter, sign-ons requested.

July 30, 1999
AIDS Treat News. 1998 Sep 4;(302):4. Unique Identifier : AIDSLINE

Treatment activists are circulating a letter opposing drug-pricing strategies for abacavir (Ziagen) and efavirenz (Sustiva). The groups are concerned that these drugs will be priced significantly higher than other nucleoside analogs and non-nucleoside reverse transcriptase inhibitors. The statement notes that higher survival rates should insure drug manufacturers of a steady supply of patients, allowing them to lower prices and still make a profit. Both drugs are appropriate for treatment-naive and treatment-experienced patients, making the potential market for them large. The letter is sponsored by the Fair Price Working Group, which includes members from Project Inform, ACT UP/New York, the San Francisco AIDS Foundation, GMHC Treatment Issues, Foundation for AIDS and Immune Research, and AIDS Treatment News. Contact information is included.

NEWSLETTER ARTICLE Anti-HIV Agents/*ECONOMICS/THERAPEUTIC USE Dideoxynucleosides/*ECONOMICS/*THERAPEUTIC USE *Economics, Pharmaceutical HIV Infections/*DRUG THERAPY/ECONOMICS Human Oxazines/*ECONOMICS/THERAPEUTIC USE Reverse Transcriptase Inhibitors/*ECONOMICS/THERAPEUTIC USE United States

www.aegis.org